9776 — Sapporo Clinical Laboratory Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesConservativeMicro CapSuper Stock

Annual income statement for Sapporo Clinical Laboratory, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	17,659	17,503	19,110	20,128	19,682
Cost of Revenue
Gross Profit	5,520	5,735	6,322	6,298	5,895
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	16,852	16,373	17,676	19,319	19,059
Operating Profit	807	1,130	1,433	809	623
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	845	1,176	1,502	960	598
Provision for Income Taxes
Net Income After Taxes	528	794	1,047	641	363
Minority Interest
Net Income Before Extraordinary Items
Net Income	528	794	1,043	569	380
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	528	794	1,043	569	380
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	179	234	327	211	99
Dividends per Share